New inhaled drug SYH2059 begins first human safety tests
NCT ID NCT07510958
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial will test the safety and tolerability of an inhaled drug called SYH2059 in 84 healthy adults. Participants will receive either single or multiple doses of the drug or a placebo. The study aims to understand how the body processes the drug and whether it causes any side effects. Since this is an early-stage trial in healthy people, it does not aim to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SYH2059 powder for inhalation
- What could go wrong
- This is a very early Phase 1 study in healthy people, so it cannot show any treatment effect. The drug may prove unsafe or ineffective in future trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates